Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Group Health Cooperative-Seattle
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Group Health Cooperative-Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Swedish Medical Center-First Hill
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Northwest Hospital
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Northwest Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
University of Washington Medical Center
mi
from
Seattle, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Olympic Medical Cancer Care Center
mi
from
Sequim, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Olympic Medical Cancer Care Center
mi
from
Sequim, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Cancer Care Northwest - Spokane South
mi
from
Spokane, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Rockwood Cancer Treatment Center-DHEC-Downtown
mi
from
Spokane, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
MultiCare Tacoma General Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Saint Joseph Medical Center
mi
from
Tacoma, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Saint Joseph Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Providence Saint Mary Regional Cancer Center
mi
from
Walla Walla, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Providence Saint Mary Regional Cancer Center
mi
from
Walla Walla, WA
Click here to add this to my saved trials
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  4/20/2016
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 4/20/2016
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer
Status: Enrolling
Updated:  5/10/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer
Status: Enrolling
Updated: 5/10/2016
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
Self-Administered Guided Imagery in the Perioperative Period to Reduce Postoperative Distress in Gynecologic Oncology Patients: A Randomized Control Trial
Status: Enrolling
Updated:  5/11/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
Self-Administered Guided Imagery in the Perioperative Period to Reduce Postoperative Distress in Gynecologic Oncology Patients: A Randomized Control Trial
Status: Enrolling
Updated: 5/11/2016
University of Michigan Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Outpatient Care Center
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Outpatient Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center-Blackburn
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center-Blackburn
mi
from
Indianapolis, IN
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center- Forest Manor
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center- Forest Manor
mi
from
Indianapolis, IN
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health West 38th Street
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health West 38th Street
mi
from
Indianapolis, IN
Click here to add this to my saved trials
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center- Pecar
mi
from
Indianapolis, IN
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center- Pecar
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Outpatient Care Center
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Outpatient Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center-Blackburn
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center-Blackburn
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Center- Forest Manor
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Center- Forest Manor
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health West 38th Street
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health West 38th Street
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated:  5/24/2016
Eskenazi Health Pecar
mi
from
Indianapolis, IN
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
Status: Enrolling
Updated: 5/24/2016
Eskenazi Health Pecar
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Electronic Catheter Stethoscope
Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery
Status: Enrolling
Updated:  5/26/2016
Women's Center Operating Rooms at the Tampa General Hospital
mi
from
Tampa, FL
Electronic Catheter Stethoscope
Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery
Status: Enrolling
Updated: 5/26/2016
Women's Center Operating Rooms at the Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated:  6/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated: 6/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated:  6/1/2016
Washington University in St Louis (Siteman Cancer Center)
mi
from
St. Louis, MO
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated: 6/1/2016
Washington University in St Louis (Siteman Cancer Center)
mi
from
St. Louis, MO
Click here to add this to my saved trials
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated:  6/1/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors
Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)
Status: Enrolling
Updated: 6/1/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated:  6/14/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated: 6/14/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated:  6/14/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated: 6/14/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated:  6/14/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated: 6/14/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated:  6/14/2016
Newton-Wellesley Hospital
mi
from
Newton, MA
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated: 6/14/2016
Newton-Wellesley Hospital
mi
from
Newton, MA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated:  6/14/2016
Massachusetts General Hospital
mi
from
Charlestown, MA
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated: 6/14/2016
Massachusetts General Hospital
mi
from
Charlestown, MA
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated:  6/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated: 6/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated:  6/14/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Status: Enrolling
Updated: 6/14/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Patient Navigation in the Safety Net:CONNECTeDD
Patient Navigation in the Safety Net:CONNECTeDD
Status: Enrolling
Updated:  6/14/2016
Boston Med Ctr
mi
from
Boston, MA
Patient Navigation in the Safety Net:CONNECTeDD
Patient Navigation in the Safety Net:CONNECTeDD
Status: Enrolling
Updated: 6/14/2016
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Mandeville, LA
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Mandeville, LA
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
LawrenceVille, NJ
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
LawrenceVille, NJ
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Lakewood, CO
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Lakewood, CO
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Little Rock, AR
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Atlanta, GA
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Toledo, OH
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Tucson, AZ
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
New Port Richey, FL
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Louisville, KY
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
North Miami, FL
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
North Miami, FL
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Louisville, KY
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Springfield, IL
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated:  6/15/2016
Clinical Research Facility
mi
from
Louisville, KY
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Status: Enrolling
Updated: 6/15/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials